
==== Front
World J Virol
WJV
World Journal of Virology
2220-3249
Baishideng Publishing Group Inc

jWJV.v13.i3.eid97973
10.5501/wjv.v13.i3.97973
97973
Review
Viral etiologies of acute liver failure
McSteen BW et al. Viral etiologies of ALF
McSteen Brian W Department of Medicine, New York-Presbyterian/Weill Cornell Campus, New York, NY 10021, United States. qqq9001@nyp.org

Ying Xiao-Han Department of Medicine, New York-Presbyterian/Weill Cornell Campus, New York, NY 10021, United States

Lucero Catherine Department of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY 10021, United States

Jesudian Arun B Department of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY 10021, United States

Author contributions: McSteen BW performed the literature review and prepared the original draft of the article; All authors were involved in the conceptualization of this work; All authors contributed to the review and editing of the article.

Corresponding author: Brian W McSteen, MD, Department of Medicine, New York-Presbyterian/Weill Cornell Campus, Weill Cornell Internal Medicine Associates 505 East 70th Street, New York, NY 10021, United States. qqq9001@nyp.org

25 9 2024
25 9 2024
13 3 9797314 6 2024
7 8 2024
19 8 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
Acute liver failure (ALF) is a rare cause of liver-related mortality worldwide, with an estimated annual global incidence of more than one million cases. While drug-induced liver injury, including acetaminophen toxicity, is the leading cause of ALF in the Western world, viral infections remain a significant cause of ALF and the most common cause in many developing nations. Given the high mortality rates associated with ALF, healthcare providers should be aware of the broad range of viral infections that have been implicated to enable early diagnosis, rapid treatment initiation when possible, and optimal management, which may include liver transplantation. This review aims to provide a summary of viral causes of ALF, diagnostic approaches, treatment options, and expected outcomes.

Acute liver failure
Viral hepatitis
Hepatitis B
Hepatitis C
Hepatitis A
Liver disease
Hepatology
==== Body
pmc Core Tip: Acute liver failure (ALF) is a rare cause of liver-related mortality worldwide, with viral infections remaining a leading global cause. Healthcare providers should be aware of the broad range of viral etiologies that have been implicated to cause ALF given its heterogeneous presentations and high mortality rate. This review aims to provide a summary of known viral etiologies for ALF so that early diagnosis, rapid treatment initiation when possible, and optimal management including liver transplantation can be pursued. Further, this review intends to underscore the importance of further study and characterization of ALF to improve our care and understanding of this condition.

INTRODUCTION

Acute liver failure (ALF) is a rare condition which presents heterogeneously. ALF is clinically characterized by severe acute liver injury (ALI) for less than 26 weeks in duration, impaired hepatic synthetic function as indicated by an elevated international normalized ratio of greater than 1.5, and encephalopathy in a patient without cirrhosis or other pre-existing liver disease[1]. The development of ALF is associated with high morbidity and mortality and is an indication for emergency liver transplant (LT) evaluation. The global incidence of ALF is estimated to be more one million cases annually[2]. Mortality rates are drastically higher in low and middle-income countries compared to upper-middle and high-income countries[3]. Etiologies of ALF vary considerably between geographic regions. While acetaminophen and other drug-induced liver injury comprise most ALF cases in countries such as the United States and the United Kingdom, acute viral hepatitis remains the most common cause of ALF in many other parts of the world[4]. The precise global burden of viral-induced ALF has historically been difficult to determine given challenges employing diagnostic criteria, accurate diagnosis of viral-infections, and the relative rarity of ALF[3]. Numerous viral pathogens have been implicated in ALF, including hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella zoster virus (VZV), parvovirus B19, herpes simplex virus (HSV), yellow fever (YF), dengue virus (DENV), and human adenovirus (HAdV). Table 1 summarizes high-yield points from this review.

Table 1 Known viral etiologies of acute liver failure with associated viral genetic material, common symptoms, diagnostic approach, possible treatment options, indication for liver transplant and whether a vaccine is available

Virus	Virus genetic material	Symptoms	Diagnosis	Possible treatment options	Indication for LT evaluation in ALF?	Dedicated vaccine available?	
HAV	RNA	Diarrhea, fever, malaise, anorexia, nausea, vomiting, abdominal pain, headache	Serologic	Supportive	Yes	Yes	
HBV	DNA	Anorexia, jaundice, abdominal pain, constitutional symptoms	Serologic + viral DNA	Entecavir, tenofovir	Yes	Yes	
HCV	RNA	Fatigue, myalgia, low-grade fever, nausea, vomiting, jaundice	Serologic + viral RNA	DAA requires further study in ALF	Yes	No	
HDV	RNA	Fatigue, anorexia, lethargy, nausea	Serologic + viral RNA	Requires further study in ALF, demonstrated effectiveness of bulevirtide + peginterferon alfa-2α in chronic HDV	Yes	No	
HEV	RNA	Fatigue, anorexia, lethargy, nausea	Viral RNA	Ribavrin, glycyrrhizin	Yes	Yes2	
CMV	DNA	Pharyngitis, lymphadenopathy, arthralgia, lymphocytosis, splenomegaly, hepatitis	Serologic + viral DNA	Transplantation in ALF; ganciclovir, valganciclovir, foscarnet and cidofovir in ALI	Yes	No	
EBV	DNA	Fever, sore throat, lymphadenopathy, mononucleosis syndrome	Viral DNA	Acyclovir, ganciclovir, famcilovir, valganciclovir +/- corticosteroids	Yes	No	
VZV	DNA	Blistering, erythematous rash, “shingles”	Viral DNA	Acyclovir, IVIG1	Yes	Yes	
Parvovirus B19	DNA	Erythema infectiosum: Fever, rash, arthralgias	Serologic	IVIG, hydroxyurea, cidofovir/brincidofovir, coumarin	Yes	No	
HSV	DNA	Painful oral or genital sore; non-specific systemic symptoms	Serologic + viral DNA	Acyclovir	Yes	No	
YF	RNA	Fever, headache, myalgias, nausea	Serologic + viral RNA	Sofosbuvir1	Yes	Yes	
SARS-CoV-2	RNA	Upper and/or lower respiratory tract infection, cough, fever, anorexia	Serologic or viral RNA	Supportive	Yes	Yes	
DENV	RNA	Fever, headache, body pains, chills, sore throat, rash	Serologic or viral RNA	NAC1	Yes	Yes	
HAdV	DNA	Localized upper or lower respiratory tract infection, gastroenteritis	Histologic4	Cidofovir	Yes	Yes3	
1 Requires further study.

2 Only available in China.

3 Only routinely available for military recruits.

4 May require further testing for human adenovirus speciation.

ALT: Acute liver failure; LT: Liver transplant; HAV: Hepatitis A virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HDV: Hepatitis D virus; HEV: Hepatitis E virus; CMV: Cytomegalovirus; EBV: Epstein-Barr virus; VZV: Varicella zoster virus; HSV: Herpes simplex virus; YF: Yellow fever; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; DENV: Dengue virus; HAdV: Human adenovirus; ALI: Acute liver injury; DAA: Direct-acting antivirals; IVIG: Intravenous immune globulin; NAC: N-acetylcysteine; ALF: Acute liver failure.

HAV

HAV is a nonenveloped RNA virus transmitted by fecal-oral contamination that is endemic in all parts of the world[5]. HAV has an incubation period of about 28 days and typically causes a self-limited diarrheal illness. The acute HAV clinical course consists of a pre-icteric phase of about one week of fever, malaise, anorexia, nausea, vomiting, abdominal pain, and headache followed by an icteric phase which can persist for a month or more[6]. Symptomatic disease seems to be age-related; around 70% of infected adults develop jaundice, compared to 30% of infected children[6]. An estimated 0.1%-0.5% of acute HAV infections progress to ALF[7]. HAV replicates in hepatocytes and the gastrointestinal epithelium. Hepatocellular injury in HAV is attributed to a cytotoxic response to virus-infected cells[8]. Cytotoxic damage from natural killer (NK), NK T-cells, non-HAV specific CD8+ T-cells, and virus-specific cytotoxic T-cells have been shown to contribute to hepatocyte injury and death. There is also emerging evidence that HAV can induce intrinsic apoptosis of hepatocytes in animal models. Virus-specific cytotoxic T-lymphocytes can cause direct hepatocellular injury via cell lysis[9]. Non-virus specific lymphocytes are also thought to contribute to hepatocellular injury; this has been demonstrated in a study from Kim et al[10] where high levels of interleukin (IL)-15 and upregulation of NKG2D ligands were observed in HAV-infected and uninfected hepatocytes, with severity of liver injury correlating with the activation of non-virus specific CD8+ T cells. Further, studies in mice models have suggested that type I interferon (IFN) receptor-mediated signaling may be involved in intrinsic apoptosis of HAV-infected hepatocytes[9]. HAV-induced ALF can cause the histologic features of massive hepatocyte necrosis, inflammatory cellular infiltrate, and bile ductular proliferation[11]. The precise mechanism underlying progression of severe HAV infection to ALF requires further study.

Diagnosis of acute HAV is made via detection of anti-HAV immunoglobulin M (IgM) via blood testing in the appropriate clinical context. Anti-HAV IgM can typically be detected 5-10 days before symptom onset. Treatment of severe HAV is supportive, and LT evaluation is indicated for those who progress to ALF[12]. While LT for HAV is extremely rare, reported 5-year post-LT survival in this population is reported to be 69%[4].

Vaccination against HAV has considerably decreased the prevalence of acute infection. The World Health Organization (WHO) recommends universal childhood HAV vaccination in endemic countries and targeted vaccination efforts for high-risk grounds in areas of low endemicity[13]. The combined point-prevalence of HAV-induced ALF in countries with routine HAV vaccination is around 2% (95% confidence interval: 1-3), compared to roughly 27% (95% confidence interval: 13-43) in countries without routine immunization[3]. One study in Argentina showed that the incidence of HAV-induced ALF in children decreased from 54.6% (March 1993 to July 2005) to 27.7% after the implementation of routine single-dose HAV vaccine in 2005 (August 2005 to December 2008). The same study reported zero cases of HAV-induced ALF beyond November 2006[14].

HBV

HBV is a partially double-stranded circular DNA virus and one of the leading causes of chronic hepatitis, cirrhosis, and hepatocellular carcinoma worldwide. It is estimated that < 0.5% to 1% of persons who experience acute or reactivation of HBV will progress to HBV-induced ALF[15,16]. Acute HBV has an incubation period of 1-4 months. Initial illness symptoms can include a serum sickness-like illness followed by anorexia, jaundice, abdominal pain, and constitutional symptoms[16]. Mortality resulting from HBV-induced ALF is high, with LT-free survival of about 25%[4]. While the pathophysiology of hepatic necrosis is not fully understood, HBV core promoter mutations encourage enhanced viral replication, strong humoral immunity response (evidenced by massive accumulation of IgG and IgM secreting plasma cells in necrotic hepatic tissues of patients with HBV-induced ALF), and intrinsic viral induction of apoptosis may contribute to the development of ALF[12]. Mice models have shown that hepatocellular damage is also mediated by cytokines including tumor necrosis factor (TNF)-α and IFN-γ, sensitizing hepatocytes to immune-mediated damage and exacerbating liver injury[17]. HBV can also have direct cytopathic effects, which has been demonstrated in hepatoma models expressing HBV large-surface proteins causing vacuole formation and apoptosis and in mice models where HBV core protein has been shown to interfere with hepatocyte mitochondrial recycling, increasing apoptotic hepatocyte death[18,19]. Histologically, HBV-induced ALF is characterized by high production of IgG and IgM secondary to an overwhelming B-cell response with complement deposition leading to massive or sub-massive hepatocyte necrosis[20]. HBV is estimated to cause up to 18% of ALF cases in Europe, 15% in Bangladesh and India, 22% in Sudan, and 7% in the United States[21]. Of note, HBV can cause ALF during an acute infection as well as an acute-on-chronic flare of disease[22].

Increasing use of immunomodulating and immunosuppressive therapies in autoimmune diseases and malignancies have caused significantly more episodes of HBV reactivation, which can occur indirectly through down-regulation of cytotoxic T-cells or B-cell inhibition. Glucocorticoids and anti-TNF therapies are also capable of directly stimulating upregulation of HBV expression[23]. The Association for the Study of Liver Diseases defines HBV reactivation in people receiving cytotoxic or immunosuppressive therapy as ≥ 2 Log increase compared to baseline HBV DNA levels, ≥ 3 Log increase in a patient with previously undetectable HBV DNA levels, new appearance of HBV DNA levels in patients who are HBV surface antigen (HBsAg)-positive and anti-HBV core antigen (anti-HBc) positive, or newly detectable HBV DNA or reappearance of HBsAg in patients who are HBsAg-negative and anti-HBc-positive[24]. Patients who are HBsAg-positive are at higher risk for HBV reactivation than HBsAg-negative and anti-HBc-positive patients. HBsAg-positive patients receiving immunosuppressive/cytotoxic therapy or HBsAg-negative/anti-HBc-positive patients undergoing high-risk therapy (anti-CD20 therapy, stem cell transplantation) are recommended to receive HBV-directed antiviral prophylaxis given the high risk of viral reactivation[24]. In immunocompetent patients with HBV, interruption of HBV-directed antiviral therapy has been associated with a statistically significant risk of HBV-reactivation leading to hepatic failure and increased 28- and 90-day mortality[25].

Diagnosis of HBV as a cause of ALF is largely serologic based on the detection of anti-HBc IgM and HBsAg. HBV DNA polymerase chain reaction (PCR) testing may not result quickly enough to be of clinical utility. The hallmark of diagnosing acute HBV is the detection of anti-HBc IgM; anti-HBc IgM can become detectable 1-2 weeks after the appearance of HBsAg[26]. However, it is important to note that anti-HBc IgM can also reappear during severe reactivation flares of chronic HBV in patients receiving chemotherapeutic or immunosuppressive medications[27]. HBV DNA will be detectable in HBV-induced ALF. Previous studies have found that viral loads are lower at initial presentation for patients who progressed to ALF, perhaps reflecting a more robust immune response predisposing patients to increased hepatocyte damage. A superinfection or coinfection of another hepatitis virus, such as HDV, should also be tested for in those with suspected HBV reactivations[21]. In HBV-induced ALF, antiviral treatment is recommended with entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide[24]. Recent data suggest that early treatment may improve LT-free survival in HBV-induced ALF[28]. HBV-directed antiviral treatment should be continued indefinitely in those who undergo LT or until HBsAg clearance is confirmed[22].

The HBV vaccine is effective in preventing HBV infection and is therefore recommended by the WHO to be included in all national immunization programs[29]. HBV immunization significantly reduces the risk of complications related to HBV, including chronic liver disease, hepatocellular carcinoma, and ALF[30]. In those chronically infected with HBV, achieving functional cure (sustained loss of HBsAg and undetectable HBV DNA after a finite treatment course) has the potential to decrease HBV transmission and thereby the risk of HBV-induced ALF. A primary challenge to HBV functional cure remains the virus’ long half-life and covalently closed circular DNA, persistent production of HBsAg from integrated HBV DNA, and host immune exhaustion. The latest approaches to HBV functional cure involve combination therapy aimed to suppress HBV DNA replication and HBsAg production with subsequent stimulation of the HBV-specific immune response. Therapeutic approaches to functional HBV cure currently in testing involve viral suppression with nucleotide or nucleoside therapy in combination with pegylated IFN or immunomodulators[31].

HCV

HCV is a single-stranded RNA virus with seven identified genotypes and 67 subtypes[32]. Acute HCV leads to chronic infection in 70%-80% of cases, placing affected patients at risk of developing cirrhosis and/or hepatocellular carcinoma[33]. Acute infection with HCV is most often asymptomatic but can also present with fatigue, myalgia, low-grade fever, nausea, vomiting and jaundice[34]. HCV is thought to damage hepatocytes through several mechanisms including direct viral injury, secondary oxidative damage and host immune response. HCV can cause direct stress within the endoplasmic reticulum of hepatocytes, with HCV-encoded proteins activating pro-inflammatory molecules such as transcription factor nuclear factor-κB. HCV-infected hepatocytes increase the production of pro-fibrotic signals such as transforming growth factor-. HCV core and NS3 proteins are also thought to promote inflammation by stimulating IL-1 receptor-associated kinase activity, increasing p38 phosphorylation and activating extracellular regulated kinase and c-Jun N-terminal kinase[35]. Further, HCV infection has been shown to induce oxidative stress and cellular damage via multiple mechanisms, including of increased production of reactive oxygen species and decreased glutathione stores[36]. HCV also causes hepatocellular injury via host immune response, with cytotoxic lymphocytes destroying HCV-infected cells with the release of Fas-ligand and inflammatory cytokines, including IFN-γ and TNF, causing injury to uninfected cells[37].

HCV as an isolated cause of ALF is controversial but has been reported, and acute HCV infection is known to be capable of causing severe ALI, particularly in immunosuppressed patients[12,38]. Severely immunocompromised individuals, such as kidney or LT recipients, are also predisposed to direct HCV-induced viral injury via fibrosing cholestatic hepatitis (FCH) which is a rare, rapidly progressive form of cholestatic liver injury with marked jaundice and high HCV viral load[39]. FCH manifests histologically with hepatocyte swelling, cholestasis, periportal peritrabecular fibrosis, and mild inflammation and can progress to ALF[40]. There has also been documentation of HCV-induced ALF in patients with concurrent chronic HBV infection[41].

The gold standard for diagnosis of HCV infection is detection of HCV RNA by PCR, and routine screening for HCV infection can be performed via detection of anti-HCV antibodies. While curative HCV therapy is now widely available, the development of an HCV-vaccine is an active area of research with several neutralizing antibody candidates identified and several vaccine studies ongoing[42]. More research is required to clarify the role of direct-acting antivirals (DAA) in HCV-induced ALF. DAA treatment has shown clinical benefit and sustained virologic response in severe HCV infection including FCH[43].

HDV

HDV is a satellite RNA virus which relies on HBV for viral replication as it utilizes the HBsAg viral envelope for hepatocyte receptor viral entry. A recent systematic review estimated that the global anti-HDV prevalence to be 4.5% in those known to be hepatitis B surface-antigen positive[44]. This translates to a worldwide prevalence of HDV/HBV coinfection of 20-40 million people, although some estimates are as high as 72 millions[45]. Because HDV requires HBV to propagate, infections occur simultaneously as a coinfection or sequentially as a superinfection in patients with a preexisting HBV-infection[44]. Acute HDV infection presents non-specifically following a 3-7 week incubation period with fatigue, anorexia, lethargy and nausea followed by an icteric phase with the appearance of frank jaundice, dark urine and light-colored stools[46]. Mouse models have demonstrated that cytokine inflammation from TNF-α mediates hepatocellular injury in HDV infection[47]. In human cell models, it has also been shown that small HDV antigen may be capable of direct cellular toxicity by binding to mRNA downregulating protective proteins such as glutathione S-transferase P1[48]. Histologically, HDV-induced liver injury is similar to other viral hepatitis infections with hepatocyte necrosis, inflammatory infiltrates with lymphocytes and macrophages, and cytoplasmic eosinophilia[49]. An HDV superinfection in an HBV-infected individual tends to be more severe with a higher chance of progressing to ALF than HBV mono-infection or HBV/HDV coinfection[46].

Diagnosis of HDV is by detection of HBsAg and anti-HDV antibodies. Acute HDV infection is confirmed by the presence of HDV Ag and anti-HDV IgM[26]. However, HDV Ag is not always detectable and cannot necessarily help distinguish between resolved, chronic or acute infections, and thus HDV RNA detection via PCR is the gold standard for HDV diagnosis when available[50]. Anti-HBV core IgM is only present in HDV/HBV coinfection and not acute HDV superinfection, providing an ability to distinguish between these two clinical scenarios[45].

As HDV requires HBV to replicate, vaccinations programs for HBV are the most effective measure to prevent HDV infection. There is no HDV-specific vaccine available. In the United States, there are no specific antiviral treatments approved for acute HDV[51]. Until the approval of bulevirtide in Europe in 2020, pegylated IFN-α was the primary drug of choice for HDV infection[45]. Bulevirtide acts by blocking the entry receptor for HBV/HDV on hepatocytes, sodium taurocholate co-transporting polypeptide[52]. A recently published study from Asselah et al[53] in patients chronically infected with HDV showed that combination bulevirtide plus peginterferon alfa-2a was superior to bulevirtide alone in achieving undetectable serum HDV RNA. Treatment of HDV should also focus on treatment of concurrent HBV infection[54]. For HDV-induced ALF, data are lacking regarding treatments including bulevirtide, and the definitive therapy is LT[45].

HEV

HEV is a nonenveloped single-stranded RNA virus with eight genotypes that is most often transmitted via the fecal-oral route involving contaminated water[55]. HEV is the most common cause of acute viral hepatitis worldwide, with HEV1 and HEV2 (likely human reservoir) usually leading to self-limiting acute viral hepatitis while and HEV3 and HEV4 (thought to be zoonotic viruses with the primary animal host being pigs) have been found to cause chronic hepatitis in immunocompromised patients[55,56]. The estimated incidence of HEV is observed to vary by region, with an estimated 2 million cases annually in Europe and 3.4 million symptomatic cases annually in Asia[56,57]. Hepatitis E outbreaks are usually related to contaminated drinking water reservoirs. Pregnant women are most likely to be affected during outbreaks. Further, acute HEV has been found to progress to ALF more often in pregnant women (22%) compared to non-pregnant women (0%) and men (2%)[58]. Liver injury in HEV-induced ALF is thought to primarily be driven by immune response to HEV infection[59]. HEV is thought to cause hepatocyte damage via host immune response in the presence of pro-inflammatory cytokines TNF-α and IFN-γ; direct HEV cytotoxic effects are an active area of inquiry[58]. HEV-induced ALF has been noted to be histologically heterogenous, attributed to the diversity of prevalent genotypes. However, a study of 11 biopsies from HEV-induced ALF showed varying degrees of necrosis, ballooning hepatocyte degeneration (70%), councilman bodies (90%), pseudo-rosettes (70%), Kupffer cell prominence (100%), intracytoplasmic (80%) and canicular (90%) cholestasis, biliary ductular proliferation (90%) and less plasma cell portal inflammation (20%)[60]. While HEV-related mortality is typically comparable to that seen with other acute viral hepatitis infections (0.2%-1%), the mortality rate among pregnant women is estimated to be as high as 20%. The hypothesized mechanism for the increased risk of ALF in pregnancy is related to immunologic changes discouraging antigenic sensitization to the fetus, causing decreases in cellular immunity which predispose to more severe HEV disease[61].

The rapid diagnosis of HEV with indirect immunoglobulin assays is complicated by virologic heterogeneity and lack of understanding of how different HEV genotypes influence the production of diagnostic antigens, making these results difficult to interpret in acute disease[62]. In a recent case series of ALF in the United States attributed to drug-induced liver injury, 9 of 318 cases reviewed had serologic evidence of ongoing acute HEV infection with positive anti-HEV IgM, while 4 of the cases had detectable HEV3 RNA in the serum. Therefore, acute HEV may comprise a small but significant percent of ALF cases of indeterminate cause[63]. Direct testing by HEV PCR, if available, may provide the highly sensitive and specific diagnostic screening test that is required in severe, acute HEV infection[62].

A vaccine against HEV, HEV 239, has been available in China since 2012, but is not presently available in other countries. A phase 3 double-blind placebo-controlled study of this vaccine demonstrated a 10-year efficacy of 83.1% in intention-to-treat analysis and 86.6% in the per protocol analysis and was shown to induce durable anti-HEV antibodies for at least 8.5 years[64]. Despite promising data for HEV 239 in China, the WHO’s current position is that available data are insufficient for children under 16 years old as well as cross-protection against HEV genotypes 1, 2 and 3. The WHO does not currently recommend that HEV 239 be incorporated into routine vaccination programs[65]. While there is no established treatment for HEV-induced ALF, ribavirin monotherapy has been shown to encourage viral clearance in immunocompetent and immunosuppressed patients experiencing severe, acute HEV infection. While ribavirin is otherwise contraindicated during pregnancy due to teratogenic effects, case studies have reported normal pregnancy outcomes after fetal ribavirin exposure, suggesting that treatment with ribavirin may outweigh the risk of untreated HEV in pregnancy[66]. There is also low-quality evidence in acute moderate to severe HEV that glycyrrhizin, an extracted component of licorice root, can lead to clinical improvement and normalization of ALT and AST within 30 days of commencing therapy[67]. In chronically infected immunosuppressed solid-organ patients, ribavirin improves viral clearance and sustained virologic response[68]. Unfortunately, a safe ribavirin doses has not been established for HEV-related ALF. Further research should focus on whether the availability of the HEV 239 reduces the incidence of HEV-induced ALF and other associated complications.

CMV

CMV is a double-stranded DNA herpesvirus with a worldwide seroprevalence of 60%-100%. While CMV can cause clinically significant disease with high morbidity and mortality in immunocompromised populations, only 10% of immunocompetent individuals present with symptomatic infection. Reported symptoms are often mild and self-limited, including pharyngitis, lymphadenopathy, arthralgia, lymphocytosis, splenomegaly, and hepatitis[69]. CMV hepatitis causes non-specific symptoms, and cases of ALF attributed to CMV are exceedingly rare[70,71]. While CMV can cause direct cytopathic damage to hepatocytes and cholangiocytes, immune-mediated CD8+ T-cell response and cytokines IFN-γ and TNF has been shown in mouse models to be important to the progression of CMV hepatitis in severe cases[72]. While no diagnostic criteria exist for CMV-induced ALF, an active CMV infection is diagnosed by a detectable CMV DNA PCR test in combination with a positive CMV IgM or an increase in CMV IgG greater than 4-fold the upper limit of normal[69]. Liver biopsy can assist in cases of diagnostic uncertainty. Histologic features of CMV hepatitis include the presence of cytoplasmic and intranuclear inclusion bodies, lobular hepatitis, hepatocellular necrosis, portal mononuclear infiltrates and micro-abscesses[73].

Immunosuppressed individuals, especially solid-organ transplant recipients, are at highest risk of CMV-related complications. There is no CMV vaccine available, and prevention in immunosuppressed individuals is primarily achieved with prophylactic antiviral medications. Valganciclovir and ganciclovir are common choices for CMV viral prophylaxis in LT, and immunosuppressed, patients[74]. While letermovir has been shown to be effective in hematopoietic stem cell transplants, a recently published case series suggests that letermovir may be effective for secondary CMV-prophylaxis in solid organ transplant patients, including LT patients[75]. For CMV-related hepatitis, treatment targets the CMV DNA polymerase and ganciclovir, valganciclovir, foscarnet and cidofovir have been used[73]. However, once CMV-induced hepatic injury has advanced to ALF, it is thought to be unresponsive to antivirals and is therefore an indication for emergent LT evaluation. Suppressive antiviral therapy is essential in patients who undergo LT, as CMV-induced ALF is an identified risk factor for clinically significant CMV disease following LT[69,76]. Further study of comparative effectiveness of treatments for acute CMV-induced hepatitis and whether there are differences in progression to ALF are needed.

EBV

EBV is a double-stranded DNA herpesvirus with a seroprevalence of over 90% worldwide. Infection most commonly causes mild, self-limited fever, sore throat, lymphadenopathy, and mononucleosis syndrome[77]. EBV preferentially infects B lymphocytes by binding the gp350 glycoprotein on CD21. Although EBV can cause a mild subclinical and self-limiting hepatitis as a part of the mononucleosis syndrome, it can also cause ALF. Patients at risk present with a triad of atypical lymphocytosis, splenomegaly, and jaundice. Interestingly, EBV-induced ALI tends to predominantly present in a cholestatic pattern of injury[78]. EBV is nonhepatotropic, and instead is understood to cause hepatic damage via EBV-infected lymphocytes with subsequent predominant CD8+ T-cell immune response causing inflammation and hepatocellular damage[79]. Histopathology typically shows diffuse lymphocytic sinusoidal infiltrates in a string of beads pattern, a lymphocytic infiltrate causing expansion of portal tracts, and, in severe cases, massive hepatic necrosis[73]. Immunosuppression is thought to be a risk-factor for severe disease related to viral reactivation in EBV-exposed individuals[80]. A study from the United States Acute Liver Failure Study Group found that only 4 patients in their database of 1887 patients had ALF attributed to EBV. Of these 4, all were young, immunocompetent adults (< 30 years old) who had been experiencing symptoms for 2-3 weeks prior to presentation[81].

Diagnosis can be challenging given nonspecific pathologic biopsy findings and difficult-to-interpret EBV serum tests (including serum viral load levels)[81]. In terms of diagnostic testing, EBV DNA PCR is more reliable than EBV serologies given the high degree of cross-reactivity to other herpesviruses (e.g., CMV and HEV). EBV IgG, IgM, and heterophile antibody testing can be utilized for initial screening[73]. Ancillary studies such as EBV-encoded RNA histopathologic testing can be used as an additional diagnostic study when available but does not exclude EBV-hepatitis as a diagnosis[82]. Definitive diagnosis of EBV-associated ALF is made by DNA detection by PCR in the appropriate clinical context.

There is currently no EBV vaccine available. Research for an EBV-vaccine is of interest given the virus’ implication in multiple malignancies and auto-immune conditions; however, vaccine development is complicated by the virus’ complex life cycle, lack of robust animal models, and uncertainty around optimal antigen target and delivery methods[83]. Some of the latest EBV vaccine candidates utilize poxvirus and adenovirus vectors or peptide vaccines[84]. In terms of treatment, the antiviral agents acyclovir, ganciclovir, famcilovir, and valganciclovir, sometimes in combination with corticosteroids, are utilized for EBV-associated hepatitis and severe EBV-disease[69,81]. The relative efficacy of respective antiviral regimens in EBV-induced ALF has yet to be established. However, the United States Acute Liver Failure Study Group recommends initiation of antiviral treatment in severe EBV hepatitis based on available reports. Ultimately, EBV-induced ALF is an indication for LT evaluation[81].

VZV

VZV, or human herpesvirus 3, is double-stranded DNA virus that typically causes the mild disease known as chickenpox. This virus then becomes quiescent in ganglionic neurons and can reemerge as herpes zoster, or shingles, which classically causes a blistering, erythematous, and painful rash in a dermatomal distribution[85]. Disseminated VZV infection is rare and typically only arises in immunocompromised individuals such as those taking immunosuppressive therapies[86]. ALF in disseminated VZV is extremely rare. A literature review from Fang et al[86] found 18 case reports, 12 of which occurred in immunocompromised patients. Of the remaining 6 patients, 3 had recently started oral steroid therapy. This study reported a case fatality rate of 77.8%. Documented initial presentations can be nonspecific, including fever, abdominal pain, nausea, vomiting and rash, or isolated chest pain[86]. VZV has been shown to have direct hepatocellular toxicity with intracellular replication with further liver injury thought to be caused by immune-mediate responses to infection[87]. Histologically, necrosis, micro-abscesses, infiltration of inflammatory cells and eosinophilic nuclear bodies have been described[88]. Diagnosis of disseminated Varicella is made by DNA PCR detection of VZV[89].

There are no guidelines for treatment of VZV-induced ALF. Acyclovir is typically administered when VZV-induced ALF is considered, and delays in its initiation should be avoided. Fang et al[86] found that of 3 patients with ALF who received intravenous immune globulin, 2 survived, suggesting a possible benefit. Given the rarity of VZV-induced ALF in immunocompetent patients, the American Gastroenterological Association conditionally recommends against routine VZV screening in immunocompetent patients presenting with ALF[90]. VZV-induced ALF is an indication for LT evaluation, and outcomes have been reported to be favorable[91].

The VZV vaccine is a live-attenuated vaccine which is recommended for all healthy patients. The WHO recommends including the VZV vaccine in all universal routine vaccination schedules[92]. The VZV vaccine is not recommended for highly immunocompromised patients including primary immunodeficiency, solid organ transplant recipients, patients receiving active chemotherapy, human immunodeficiency virus infection with CD4 cell count < 200 × 109/L, high dose corticosteroid therapy ≥ 20 mg prednisone for at least 14 days, and some stem cell transplant patients owing to concerns regarding low likelihood of response[93]. While widespread VZV vaccination remains a WHO public health goal, trends in epidemiology and cost-effectiveness of the vaccination have led to slow adoption of universal VZV vaccination[94].

PARVOVIRUS B19

Parvovirus B19 is a single-stranded DNA virus and part of the Parvoviridae family that infects and replicates in erythroid precursor cells. It is commonly known to cause erythema infectiosum or “fifth disease”, characterized by fever and rash in children as well as rash with clinically significant arthralgias in adults[95]. Parvovirus B19 can also infect hepatocytes and other cells that possess globosides and glycospingolipids in their cell membrane and induce apoptosis[96]. Parvovirus B19 is thought to cause hepatocyte damage primarily through direct cytopathology of the NS1 protein which is capable of binding and cleaving both host and viral and host DNA, resulting in damage that ultimately leads to hepatocyte apoptosis via the caspase pathway[97]. Histologically, these mechanisms are reflected in parvovirus B19-induced ALF biopsy specimens which demonstrate confluent necrosis with evidence of widespread hepatocyte apoptosis referred to as hepatocellular dropout[98].

While hepatitis related to parvovirus B19 infection is estimated to occur in 4.1% of patients infected, parvovirus B19-induced ALF remains an extremely rare clinical entity[96]. Diagnosis of acute parvovirus B19 disease relies on detection of anti-parvovirus B19 IgM, which may not become detectable until 10-14 days post-infection. Direct testing for parvovirus B19 DNA may be the preferred method in immunocompromised individuals or those with suspected severe acute infection[26]. Most of the literature relating to ALF in acute parvovirus B19 infection involves children. Case reports in adults have described an acute hepatitis with spontaneous remission, indicating that parvovirus B19 disease is generally less severe in this population. Treatment of severe parvovirus B19 is typically symptom-directed (e.g., transfusions to treat anemia, non-steroidal anti-inflammatory drugs for arthralgia, etc). Studies regarding management of parvovirus B19-related ALF are lacking, although administration of large-doses of human intravenous immune globulin are thought to contain high levels of anti-parvovirus B19 antibodies capable of reducing viral load[99]. Novel therapies actively being studied for parvovirus B19 include hydroxyurea given its antiproliferative effect on erythrocytes, cidofovir and brincidofovir given their broad activity against DNA viruses, and newer coumarin derivatives and flavonoid molecules. However, these candidates are not being studied specifically in parvovirus B19-associated hepatitis or ALF[99]. Future study of these treatments may inform whether they also reduce the incidence or severity of liver injury in parvovirus B19 infection. LT evaluation and transplantation has been reported for parvovirus B19-induced hepatitis progressing to ALF[100,101]. There are no currently available vaccines against parvovirus B19, although development of a vaccine is an area of active inquiry[102].

HSV

HSV types 1 and 2 are double-stranded DNA viruses. Infections with HSV are common, with estimates in 2016 of 491 million people living with HSV type 2 (genital) infection and 3583.5 million living with HSV type 1 (oral) in people younger than 50 years old[103]. HSV-induced hepatitis is a rare complication which commonly leads to ALF in 74% of cases. It is associated with a mortality rate of 90% due to delayed diagnosis and treatment. Diagnosis of HSV hepatitis can be complicated by non-specific presenting symptoms. For example, more than half of patients with HSV-associated hepatitis present without mucocutaneous lesions. Anicteric hepatitis with low or normal bilirubin levels but profound transaminase elevations is common in HSV-induced hepatitis and ALF[104]. HSV has direct cytopathic effects, with mouse models showing that infection results in DNA-fragmentation and activation of caspase-3 enzyme and Fas-ligand, facilitating rapid hepatocyte apoptosis[105]. Histologically, HSV-induced ALF is characterized by coagulative necrosis, Cowdry’s type A intranuclear inclusion bodies, evidence of hepatocyte apoptosis and inflammatory cell infiltrates (notably lymphocytes and plasma cells)[106].

Diagnosis of HSV-induced ALF can be challenging. In a small study of patients with ALF (n = 63), 6 of the patients with an indeterminate cause of ALF and 1 of the patients with pregnancy-related ALF were found to have positive HSV IgM antibodies but a negative HSV-PCR, while all 4 of the patients with confirmed HSV-induced ALF had high viral load by HSV PCR (only 2 of which had a positive HSV IgM)[107]. This indicates that when HSV-associated ALF is suspected or the diagnosis is unclear, detection of HSV DNA in the blood by PCR should be pursued early. While no specific guidelines exist for treatment of HSV-induced ALF, acyclovir treatment has been associated with reduced mortality and a decreased need for LT[69]. Further, pregnant patients and neonates are at higher risk for developing disseminated HSV, with mortality rates in pregnant patients approaching 40% in HSV-induced hepatitis. Acyclovir has been shown to have favorable survival outcomes in HSV-induced hepatitis in pregnancy and be of no additional risk to the fetus, justifying early empiric administration in pregnant women when HSV-induced hepatitis is suspected[108]. LT evaluation is indicated for HSV-associated ALF, and lifelong suppressive antiviral therapy is recommended following transplant given the risk of recurrence of disseminated HSV[69].

There is no vaccine available for HSV type 1 or 2. Vaccine development to date has been hampered by viral latency and HSV’s ability to evade the innate and adaptive immune system. While a preventative vaccine against HSV is the ultimate goal, there is also active research into therapeutic vaccines that may discourage reactivation of latent infection. There are presently multiple vaccine candidates against HSV in various stages of development[109].

YF VIRUS

VF virus is a mosquito-borne positive-single-stranded RNA flavivirus. YF is endemic to areas of Africa and Central/South America. It is transmitted by the Aedes mosquito in Africa and the Haemagogus or Sabethes species in South America. YF virus presents primarily with mild and self-limited disease characterized by fever, myalgias, headache, and nausea following an incubation period of 3-6 or up to 15 days[110]. YF can directly infect hepatocytes, with a study from da Costa Lopes et al[111] demonstrating that hepatocyte injury in VF infection may be associated with increased apoptosis, as evidenced by the presence of associated markers, caspase 3, caspase 8, BAX, Fas, Fasl, granzyme B and survivin. Histologically, YF-induced liver injury shows lytic midzonal hepatocyte necrosis, hepatocyte apoptosis, and portal and acinar inflammatory infiltrate disproportionate to the extent of hepatic injury observed[112].

Diagnosis of YF is typically based on clinical suspicion and requires serologic confirmation via detection of VF IgM or YF RNA PCR[113]. Around 12% of patients develop severe YF with involvement of various organ systems, including ALF[110]. Once severe YF develops, the treatment is supportive. IFN-α and high-dose ribavirin have not proven to be effective[114]. There is emerging evidence that the anti-HCV antiviral, sofosbuvir, may have therapeutic benefit in severe YF-related disease. This remains an area of study in Brazil given the ongoing YF outbreak in the country[115,116]. LT for YF-induced ALF has been reported in small studies. One such study of 7 LT patients with YF-induced ALF showed that 3 survived, while the 4 who died had histologic evidence of graft-infection with YF[117]. Further study of patients who undergo LT for YF-induced ALF is needed.

A live virus vaccine is available against YF. The YF vaccine is recommended for those aged ≥ 9 months who are traveling to or living in endemic areas; the vaccine is contraindicated in people with a history of thymoma/thymus dysfunction, acquired immunodeficiency syndrome, or those receiving immunosuppressive drugs or chemotherapies[118,119]. The WHO recommends routine YF vaccine to all infants ≥ 9 months, at the same time as the measles vaccine in areas with reported YF cases, and for YF surveillance so that reactive mass-vaccination programs can be launched in response to outbreaks[120]. The YF vaccine is intended to reduce the risk of people developing severe YF-disease[119]. Further study to understand whether vaccination reduces the incidence of YF-induced ALF is needed, although the low number of annual events poses a barrier to the timeliness of reaching this conclusion.

SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

The novel strain of coronavirus, an RNA virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). While ALF has been observed in patients with COVID-19 disease, treatment with hepatotoxic medications including remdesivir and acetaminophen as well as hypoxic liver injury secondary to pulmonary disease and micro-thrombosis may be responsible for these cases as opposed to a direct hepatotoxicity of SARS-CoV-2 virus[121,122]. A potential mechanism for direct viral injury to hepatocytes involves binding to the angiotensin-converting enzyme 2 receptor on cell surfaces following by S-protein activation by transmembrane protease serine 2, both of which are present on liver parenchymal cells and cholangiocytes. While COVID-19-related hepatitis and cholangiopathy are well documented, case reports of ALF without respiratory disease are very rare. Furthermore, pathologic analyses of related liver specimens have demonstrated confounded by features of hypoxia or ischemia; studies to date imply that direct viral infection of the liver is uncommon in COVID-19[123]. The pathogenicity of SARS-CoV-2 as a potential cause of ALF requires further study.

COVID-19-induced ALF has sparing case reports, with the two identified for this review documenting resolution of ALF without requiring LT[124,125]. However, there are documented cases of COVID-19-associated cholangiopathy and sclerosing cholangitis requiring LT evaluation and ultimate organ transplantation[126,127]. Further study of SARS-CoV-2 is needed to clarify risks and natural course of hepatobiliary manifestations of COVID-19.

Vaccines against SARS-CoV-2 remain widely available in the United States. On 5 May 2023, COVID-19 was no longer considered a public health emergency by the WHO; given high rates of population immunity the organization only recommends routine revaccination in special populations including pregnant people, older adults, those who are immunocompromised, and healthcare workers[128]. Vaccination has been shown to reduce the severity of COVID-19 infection and reduce the risk of liver function abnormalities in patients with metabolic-dysfunction associated steatotic liver disease[129]. Available research does not address whether SARS-CoV-2 vaccination modifies individual risk for developing ALF in COVID-19 disease but may be an area of future inquiry.

DENV

DENV is an RNA virus carried principally by the Aedes mosquito vector in tropical and subtropical regions of the world. It is caused by a flavivirus with four distinct subtypes (DENV-1, DENV-2, DENV-3, and DENV-4) defined by different antigens. DENV is estimated to have an incidence of around 400 million cases and causes 22000 deaths worldwide per annum[130]. DENV classically presents in the febrile phase as an acute illness with headache, body pains, chills, sore throat, rash (petechiae or ecchymosis) and laboratory evidence of thrombocytopenia and leukopenia. DENV can defervesce and resolve or enter the critical phase of illness with severe capillary leakage, shock and organ damage[131]. The reported incidence of DENV-induced ALF in adults ranges from 0.31%-0.71%, with younger adults being at higher risk[132]. The pathophysiology of ALF in DENV fever is hypothesized to occur via direct cytopathic effects of the virus infecting endothelial cells, Kupffer cells and hepatocytes causing cell damage and apoptosis and indirectly via host immune response to infection, microvascular leakage and shock[133].

Diagnosis of dengue is most commonly made by detection of dengue RNA or NS1 antigen during the first 7 days of illness or via DENV IgM after day 4[130]. While treatment of DENV is typically supportive, small studies in DENV-induced ALF suggest that N-acetylcysteine (NAC) may be beneficial in this population. Giri et al’s scoping review found a retrospective cohort study of 33 pediatric patients with DENV-associated ALF in Thailand that demonstrated a recovery rate of 75% for those treated with NAC versus 53% in those who received standard medical treatment, although the results were not statistically significant[132]. Another case series found a potential benefit of NAC in reducing the severity of ALF in DENV infection but no survival benefit[132]. LT for DENV-induced ALF is not common but has been reported. A recently published case series from Rajakumar et al[134] reported four cases of DENV-induced ALF, two of which recovered spontaneously and two required LT with one dying immediately post-transplant. Clinicians evaluating a patient for ALF should consider DENV as a cause if a patient has recently traveled to an endemic area.

There is a DENV vaccine available, CYD-tetravalent DENV vaccine, which has been shown to reduce the risk of severe DENV disease in secondary or subsequent infection where the risk for severe disease is higher[135]. The WHO recommends the use of CYD-tetravalent DENV vaccine in individuals ≥ 9 years old with serologic evidence of a previous DENV infection. In May of 2024 with the advent of data from the TAK-003 DENV vaccine, the WHO updated their recommendation encouraging countries to consider the introduction of TAK-003 into routine immunization programs, targeting children aged 6-16 years, in areas of high DENV transmission[136]. Further study is needed to understand if countries adopt TAK-003 in line with the WHO’s recommendation, and whether routine administration of vaccines confer protection against DENV-induced ALF.

HADV

HAdV is a non-enveloped double-stranded DNA virus which can cause mild, localized upper or lower respiratory tract infections, keratoconjunctivitis, and gastroenteritis in immunocompetent hosts[137]. HAdV has more than 100 genotypes and 52 serotypes identified to date. HAdV has been further classified into seven species, HAdV-A through -G, with different species demonstrating different affinities for various tissues of the body[138]. HAdV species A, F and G target the gastrointestinal tract and are known to cause gastroenteritis and diarrhea. In 2022, there was a documented outbreak of severe hepatitis in otherwise healthy young children in countries around the world, with more than 1000 children requiring hospitalization. In the United States, the CDC reported 6% of children in this cohort ultimately required LT, and 4% died. 299 of these patients were tested for HAdV, with 45% testing positive. HAdV-F41 was the most common HAdV species identified[139].

HAdV as a cause for severe ALI or ALF is extremely rare, predominantly occurring in immunocompromised hosts such as solid organ transplant recipients, bone marrow transplant recipients, or patients receiving active chemotherapy[140]. HAdV-induced ALF has a high mortality rate, estimated around 60%[137]. While not entirely understood, HAdV causes liver injury via direct cellular cytotoxicity and apoptosis, with viral uptake in hepatocytes and Kupffer cells having been demonstrated to be facilitated at least in part by viral binding to coagulation factor IX and complement component C4[141]. Further, HAdV is known to cause liver toxicity via immune-mediated mechanisms in response to IFN-γ and C-X-C motif ligand 9 production and signaling[142]. Diagnosis of HAdV-induced ALF can be established via liver biopsy, with possible histopathologic findings showing nonzonal coagulative hepatic necrosis, hepatocyte and intranuclear viral inclusions, and possible lack of inflammation[143]. When available, serum HAdV viral load may help support the diagnosis of HAdV-induced ALF in the appropriate clinical context[137].

Routine HAdV vaccination is only recommended for military recruits in the United States, who obtain a live oral vaccination for HAdV type 4 and type 7 to prevent febrile acute respiratory disease[144]. The WHO does not have specific HAdV vaccination recommendations. For treatment of HAdV-induced ALF, there is some indication, primarily in pediatric patients with ALI/ALF, that early administration of cidofovir may be an effective therapy[145,146]. In severe disease that has progressed to ALF, LT evaluation is warranted, and good graft function and post-transplant survival has been reported[147]. HAdV should be included as part of an initial broad diagnostic evaluation in a patient with a clinical and laboratory picture concerning for ALF, particularly in the setting of a viral-like illness. Further research of HAdV, and especially research into species and subspecies known to have gastrointestinal and hepatic tropism, is needed to understand whether HAdV is an underrecognized cause for ALI and ALF.

CONCLUSION

ALF is a rare, highly morbid, and fatal condition. A variety of acute viral infections are capable of causing massive hepatic necrosis which can lead to ALF. When ALF is suspected, a broad diagnostic workup including viral and non-viral causes is necessary for rapid diagnosis, appropriate treatment, and possible referral for LT evaluation. Further research involving novel diagnostic approaches, treatment efficacy, and patient outcomes in ALF will be critical to advancing our understanding of this heterogenous condition.

Conflict-of-interest statement: Jesudian AB received consulting and speaking for Salix Pharmaceuticals, consulting for Dynavax Therapeutics, and speaking for Madrigal Pharmaceuticals. McSteen BW, Ying XH, and Lucero C have no financial conflicts to report.

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Corresponding Author’s Membership in Professional Societies: American Association for the Study of Liver Diseases, 308351.

Specialty type: Virology

Country of origin: United States

Peer-review report’s classification

Scientific Quality: Grade C

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Cheng TH S-Editor: Wang JJ L-Editor: A P-Editor: Yuan YY
==== Refs
1 Shah NJ Royer A John S Acute Liver Failure. 2023 Apr 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-
2 Devarbhavi H Asrani SK Arab JP Nartey YA Pose E Kamath PS Global burden of liver disease: 2023 update J Hepatol 2023 79 516 537 36990226
3 Patterson J Hussey HS Silal S Goddard L Setshedi M Spearman W Hussey GD Kagina BM Muloiwa R Systematic review of the global epidemiology of viral-induced acute liver failure BMJ Open 2020 10 e037473
4 Biswas S Kumar R Acharya SK Viral hepatitis-induced acute liver failure Indian J Gastroenterol 2024 43 312 324 38451383
5 Zuckerman AJ Hepatitis Viruses. In: Medical Microbiology. Galveston (TX): University of Texas Medical Branch at Galveston; 1996-
6 Brundage SC Fitzpatrick AN Hepatitis A Am Fam Physician 2006 73 2162 2168 16848078
7 Lefilliatre P Villeneuve JP Fulminant hepatitis A in patients with chronic liver disease Can J Public Health 2000 91 168 170 10927841
8 Vallbracht A Gabriel P Maier K Hartmann F Steinhardt HJ Müller C Wolf A Manncke KH Flehmig B Cell-mediated cytotoxicity in hepatitis A virus infection Hepatology 1986 6 1308 1314 3025069
9 Wang M Feng Z Mechanisms of Hepatocellular Injury in Hepatitis A Viruses 2021 13
10 Kim J Chang DY Lee HW Lee H Kim JH Sung PS Kim KH Hong SH Kang W Lee J Shin SY Yu HT You S Choi YS Oh I Lee DH Lee DH Jung MK Suh KS Hwang S Kim W Park SH Kim HJ Shin EC Innate-like Cytotoxic Function of Bystander-Activated CD8(+) T Cells Is Associated with Liver Injury in Acute Hepatitis A Immunity 2018 48 161 173.e5 29305140
11 Xie C Fenkel JM Halegoua-DeMarzio DL Civan JM Tholey DM Herrine SK Thapar M Ambelil M Arastu S Frank AM Shah AP Glorioso JM Ramirez CG Bodzin AS Maley WR Sass DA Acute Liver Failure Requiring Liver Transplantation due to Acute Hepatitis A Virus Infection Case Rep Transplant 2021 2021 5159934 34987880
12 Manka P Verheyen J Gerken G Canbay A Liver Failure due to Acute Viral Hepatitis (A-E) Visc Med 2016 32 80 85 27413724
13 World Health Organization WHO position paper on hepatitis A vaccines – October 2022 Wkly Epidemiol Rec 2022 97 493 512
14 Cervio G Trentadue J D'Agostino D Luque C Giorgi M Armoni J Debbag R Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program Hepat Med 2011 3 99 106 24367225
15 Lee WM Hepatitis B virus infection N Engl J Med 1997 337 1733 1745 9392700
16 Burns GS Thompson AJ Viral hepatitis B: clinical and epidemiological characteristics Cold Spring Harb Perspect Med 2014 4 a024935 25359547
17 Gilles PN Guerrette DL Ulevitch RJ Schreiber RD Chisari FV HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma Hepatology 1992 16 655 663 1505908
18 Foo NC Ahn BY Ma X Hyun W Yen TS Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein Hepatology 2002 36 1400 1407 12447865
19 Su Y Bu F Zhu Y Yang L Wu Q Zheng Y Zhao J Yu L Jiang N Wang Y Wu J Xie Y Zhang X Gao Y Lan K Deng Q Hepatitis B virus core protein as a Rab-GAP suppressor driving liver disease progression Sci Bull (Beijing) 2024
20 Farci P Diaz G Chen Z Govindarajan S Tice A Agulto L Pittaluga S Boon D Yu C Engle RE Haas M Simon R Purcell RH Zamboni F B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure Proc Natl Acad Sci U S A 2010 107 8766 8771 20421498
21 Ichai P Samuel D Management of Fulminant Hepatitis B Curr Infect Dis Rep 2019 21 25 31165271
22 Oketani M Uto H Ido A Tsubouchi H Management of hepatitis B virus-related acute liver failure Clin J Gastroenterol 2014 7 19 26 26183504
23 Chang Y Jeong SW Jang JY Hepatitis B Virus Reactivation Associated With Therapeutic Interventions Front Med (Lausanne) 2021 8 770124 35096867
24 Terrault NA Lok ASF McMahon BJ Chang KM Hwang JP Jonas MM Brown RS Jr Bzowej NH Wong JB Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance Hepatology 2018 67 1560 1599 29405329
25 Zhu Y Li H Wang X Zheng X Huang Y Chen J Meng Z Gao Y Qian Z Liu F Lu X Shi Y Shang J Yan H Zheng Y Qiao L Zhang Y Xiang X Dan Y Sun S Hou Y Zhang Q Xiong Y Li S Chen J Huang Z Li B Jiang X Luo S Chen Y Gao N Liu C Ji L Yuan W Li J Li T Zheng R Zhou X Ren H Zhou Y Xu B Yu R Tan W Deng G Hepatitis B Virus Reactivation Increased the Risk of Developing Hepatic Failure and Mortality in Cirrhosis With Acute Exacerbation Front Microbiol 2022 13 910549 35875559
26 Baron EJ Miller JM Weinstein MP Richter SS Gilligan PH Thomson RB Jr Bourbeau P Carroll KC Kehl SC Dunne WM Robinson-Dunn B Schwartzman JD Chapin KC Snyder JW Forbes BA Patel R Rosenblatt JE Pritt BS A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a) Clin Infect Dis 2013 57 e22 e121 23845951
27 Alexopoulou A Baltayiannis G Eroglu C Nastos T Dourakis SP Archimandritis AJ Karayiannis P Core mutations in patients with acute episodes of chronic HBV infection are associated with the emergence of new immune recognition sites and the development of high IgM anti-HBc index values J Med Virol 2009 81 34 41 19031457
28 Özden İ Kinaci E Ocak İ Çolak M Abdullah T Özcan FG Aydin O Poturoğlu Ş Successful results of early nucleos(t)ide analogue treatment for liver transplantation candidates with severe acute hepatitis B infection Eur J Gastroenterol Hepatol 2024 36 97 100 37823433
29 Hepatitis B vaccines: WHO position paper – July 2017 Wkly Epidemiol Rec 2017 92 369 392 28685564
30 Chien YC Jan CF Chiang CJ Kuo HS You SL Chen CJ Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees Hepatology 2014 60 125 132 24497203
31 Jeng WJ Lok AS How to achieve a functional cure for chronic hepatitis B infection Clin Liver Dis (Hoboken) 2024 23 e0134 38681516
32 Rabaan AA Al-Ahmed SH Bazzi AM Alfouzan WA Alsuliman SA Aldrazi FA Haque S Overview of hepatitis C infection, molecular biology, and new treatment J Infect Public Health 2020 13 773 783 31870632
33 Roudot-Thoraval F Epidemiology of hepatitis C virus infection Clin Res Hepatol Gastroenterol 2021 45 101596 33610022
34 Maheshwari A Ray S Thuluvath PJ Acute hepatitis C Lancet 2008 372 321 332 18657711
35 Yamane D McGivern DR Masaki T Lemon SM Liver injury and disease pathogenesis in chronic hepatitis C Curr Top Microbiol Immunol 2013 369 263 288 23463205
36 Choi J Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations Free Radic Biol Med 2012 52 1135 1150 22306508
37 Spengler U Nattermann J Immunopathogenesis in hepatitis C virus cirrhosis Clin Sci (Lond) 2007 112 141 155 17199558
38 Younis BB Arshad R Khurhsid S Masood J Nazir F Tahira M Fulminant hepatic failure (FHF) due to acute hepatitis C Pak J Med Sci 2015 31 1009 1011 26430449
39 Tai AW Vargas HE Chronic hepatitis C. In: Yamada’s Textbook of Gastroenterology. United States: John Wiley & Sons Ltd, 2022
40 Hori T Onishi Y Kamei H Kurata N Ishigami M Ishizu Y Ogura Y Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation Ann Gastroenterol 2016 29 454 459 27708510
41 Chu CM Yeh CT Liaw YF Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus Gut 1999 45 613 617 10486374
42 Duncan JD Urbanowicz RA Tarr AW Ball JK Hepatitis C Virus Vaccine: Challenges and Prospects Vaccines (Basel) 2020 8
43 Vukotic R Conti F Fagiuoli S Morelli MC Pasulo L Colpani M Foschi FG Berardi S Pianta P Mangano M Donato MF Malinverno F Monico S Tamè M Mazzella G Belli LS Viganò R Carrai P Burra P Russo FP Lenci I Toniutto P Merli M Loiacono L Iemmolo R Degli Antoni AM Romano A Picciotto A Rendina M Andreone P AISF-SOFOLT Study group Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis J Viral Hepat 2017 24 858 864 28370880
44 Stockdale AJ Kreuels B Henrion MYR Giorgi E Kyomuhangi I de Martel C Hutin Y Geretti AM The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis J Hepatol 2020 73 523 532 32335166
45 Muhammad H Tehreem A Hammami MB Ting PS Idilman R Gurakar A Hepatitis D virus and liver transplantation: Indications and outcomes World J Hepatol 2021 13 291 299 33815673
46 Farci P Niro GA Clinical features of hepatitis D Semin Liver Dis 2012 32 228 236 22932971
47 Usai C Maestro S Camps G Olague C Suárez-Amaran L Vales A Aragon T Hommel M Aldabe R Gonzalez-Aseguinolaza G TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection JHEP Rep 2020 2 100098 32382723
48 Chen M Du D Zheng W Liao M Zhang L Liang G Gong M Small hepatitis delta antigen selectively binds to target mRNA in hepatic cells: a potential mechanism by which hepatitis D virus downregulates glutathione S-transferase P1 and induces liver injury and hepatocarcinogenesis Biochem Cell Biol 2019 97 130 139 30153423
49 Masood U John S Hepatitis D. 2022 Sep 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-
50 Umukoro E Alukal JJ Pak K Gutierrez J State of the Art: Test all for Anti-Hepatitis D Virus and Reflex to Hepatitis D Virus RNA Polymerase Chain Reaction Quantification Clin Liver Dis 2023 27 937 954 37778778
51 Negro F Lok A Treatment and prevention of hepatitis D virus infection. [cited 14 March 2024]. Available from: https://www.uptodate.com/contents/treatment-and-prevention-of-hepatitis-d-virus-infection
52 Kang C Syed YY Bulevirtide: First Approval Drugs 2020 80 1601 1605 32926353
53 Asselah T Chulanov V Lampertico P Wedemeyer H Streinu-Cercel A Pântea V Lazar S Placinta G Gherlan GS Bogomolov P Stepanova T Morozov V Syutkin V Sagalova O Manuilov D Mercier RC Ye L Da BL Chee G Lau AH Osinusi A Bourliere M Ratziu V Pol S Hilleret MN Zoulim F Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D N Engl J Med 2024 391 133 143 38842520
54 Tu T Urban S Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections Curr Opin Virol 2018 30 68 79 29775812
55 Kamar N Dalton HR Abravanel F Izopet J Hepatitis E virus infection Clin Microbiol Rev 2014 27 116 138 24396139
56 Aslan AT Balaban HY Hepatitis E virus: Epidemiology, diagnosis, clinical manifestations, and treatment World J Gastroenterol 2020 26 5543 5560 33071523
57 Webb GW Dalton HR Hepatitis E: an underestimated emerging threat Ther Adv Infect Dis 2019 6 2049936119837162 30984394
58 Aggarwal R Jameel S Hepatitis E Hepatology 2011 54 2218 2226 21932388
59 Chen C Zhang SY Chen L Review of clinical characteristics, immune responses and regulatory mechanisms of hepatitis E-associated liver failure World J Clin Cases 2022 10 6341 6348 35979284
60 Agrawal V Goel A Rawat A Naik S Aggarwal R Histological and immunohistochemical features in fatal acute fulminant hepatitis E Indian J Pathol Microbiol 2012 55 22 27 22499295
61 Pérez-Gracia MT Suay-García B Mateos-Lindemann ML Hepatitis E and pregnancy: current state Rev Med Virol 2017 27 e1929 28318080
62 Aggarwal R Diagnosis of hepatitis E Nat Rev Gastroenterol Hepatol 2013 10 24 33 23026902
63 Davern TJ Chalasani N Fontana RJ Hayashi PH Protiva P Kleiner DE Engle RE Nguyen H Emerson SU Purcell RH Tillmann HL Gu J Serrano J Hoofnagle JH Drug-Induced Liver Injury Network (DILIN) Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury Gastroenterology 2011 141 1665 72.e1 21855518
64 Huang S Zhang X Su Y Zhuang C Tang Z Huang X Chen Q Zhu K Hu X Ying D Liu X Jiang H Zang X Wang Z Yang C Liu D Wang Y Tang Q Shen W Cao H Pan H Ge S Huang Y Wu T Zheng Z Zhu F Zhang J Xia N Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2024 403 813 823 38387470
65 Hepatitis E vaccine: WHO position paper, May 2015 Wkly Epidemiol Rec 2015 90 185 200 25935931
66 Abbas Z Afzal R Hepatitis E: when to treat and how to treat Antivir Ther 2014 19 125 131 24192696
67 Tandon A Tandon BN Bhujwala RA Clinical spectrum of acute sporadic hepatitis E and possible benefit of glycyrrhizin therapy Hepatol Res 2002 23 55 61 12084556
68 Kamar N Izopet J Tripon S Bismuth M Hillaire S Dumortier J Radenne S Coilly A Garrigue V D'Alteroche L Buchler M Couzi L Lebray P Dharancy S Minello A Hourmant M Roque-Afonso AM Abravanel F Pol S Rostaing L Mallet V Ribavirin for chronic hepatitis E virus infection in transplant recipients N Engl J Med 2014 370 1111 1120 24645943
69 Noor A Panwala A Forouhar F Wu GY Hepatitis caused by herpes viruses: A review J Dig Dis 2018 19 446 455 29923691
70 Serna-Higuera C González-García M Milicua JM Muñoz V Acute cholestatic hepatitis by cytomegalovirus in an immunocompetent patient resolved with ganciclovir J Clin Gastroenterol 1999 29 276 277 10509956
71 Shusterman NH Frauenhoffer C Kinsey MD Fatal massive hepatic necrosis in cytomegalovirus mononucleosis Ann Intern Med 1978 88 810 812 208441
72 Livingston-Rosanoff D Daley-Bauer LP Garcia A McCormick AL Huang J Mocarski ES Antiviral T cell response triggers cytomegalovirus hepatitis in mice J Virol 2012 86 12879 12890 22993151
73 Bunchorntavakul C Reddy KR Epstein-Barr Virus and Cytomegalovirus Infections of the Liver Gastroenterol Clin North Am 2020 49 331 346 32389366
74 Bruminhent J Razonable RR Management of cytomegalovirus infection and disease in liver transplant recipients World J Hepatol 2014 6 370 383 25018848
75 Jorgenson MR Kleiboeker H Garg N Parajuli S Mandelbrot DA Odorico JS Saddler CM Smith JA Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity Transpl Infect Dis 2022 24 e13766 34799964
76 Kanj SS Sharara AI Clavien PA Hamilton JD Cytomegalovirus infection following liver transplantation: review of the literature Clin Infect Dis 1996 22 537 549 8852975
77 Nowalk A Green M Epstein-Barr Virus Microbiol Spectr 2016 4
78 Kofteridis DP Koulentaki M Valachis A Christofaki M Mazokopakis E Papazoglou G Samonis G Epstein Barr virus hepatitis Eur J Intern Med 2011 22 73 76 21238898
79 Mitra S Hanumanthappa MK Sarkar S Bhalla A Minz R Ratho RK Epstein Barr Virus-Related Acute Liver Failure and Hemophagocytosis in an Immunocompetent Individual: An Autopsy Report Int J Surg Pathol 2024 32 838 844 37723947
80 Negro F The paradox of Epstein-Barr virus-associated hepatitis J Hepatol 2006 44 839 841 16554104
81 Mellinger JL Rossaro L Naugler WE Nadig SN Appelman H Lee WM Fontana RJ Epstein-Barr virus (EBV) related acute liver failure: a case series from the US Acute Liver Failure Study Group Dig Dis Sci 2014 59 1630 1637 24464209
82 Schechter S Lamps L Epstein-Barr Virus Hepatitis: A Review of Clinicopathologic Features and Differential Diagnosis Arch Pathol Lab Med 2018 142 1191 1195 30281361
83 Cai J Zhang B Li Y Zhu W Akihisa T Li W Kikuchi T Liu W Feng F Zhang J Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction Vaccines (Basel) 2021 9
84 Cohen JI Therapeutic vaccines for herpesviruses J Clin Invest 2024 134
85 Gershon AA Breuer J Cohen JI Cohrs RJ Gershon MD Gilden D Grose C Hambleton S Kennedy PG Oxman MN Seward JF Yamanishi K Varicella zoster virus infection Nat Rev Dis Primers 2015 1 15016 27188665
86 Fang C Wong J Ang WW Fulminant varicella hepatitis: a rare but lethal cause of abdominal pain BMJ Case Rep 2021 14
87 Mathur S Achari A Green L Anand BS Acute varicella hepatitis in human T-cell lymphotrophic virus types I and II infection J Gastroenterol 1996 31 273 277 8680551
88 Dits H Frans E Wilmer A Van Ranst M Fevery J Bobbaers H Varicella-zoster virus infection associated with acute liver failure Clin Infect Dis 1998 27 209 210 9675478
89 Sauerbrei A Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections Eur J Clin Microbiol Infect Dis 2016 35 723 734 26873382
90 Flamm SL Yang YX Singh S Falck-Ytter YT AGA Institute Clinical Guidelines Committee American Gastroenterological Association Institute Guidelines for the Diagnosis and Management of Acute Liver Failure Gastroenterology 2017 152 644 647 28056348
91 Alvite-Canosa M Paniagua-Martín MJ Quintela-Fandiño J Otero A Crespo-Leiro MG Fulminant hepatic failure due to varicella zoster in a heart transplant patient: successful liver transplant J Heart Lung Transplant 2009 28 1215 1216 19782606
92 Varicella and herpes zoster vaccines: WHO position paper, June 2014--Recommendations Vaccine 2016 34 198 199 26723191
93 Armstrong C IDSA releases recommendations on vaccinations in immunocompromised patients Am Fam Physician 2014 90 664 666
94 Varela FH Pinto LA Scotta MC Global impact of varicella vaccination programs Hum Vaccin Immunother 2019 15 645 657 30427766
95 Heegaard ED Brown KE Human parvovirus B19 Clin Microbiol Rev 2002 15 485 505 12097253
96 Bihari C Rastogi A Saxena P Rangegowda D Chowdhury A Gupta N Sarin SK Parvovirus b19 associated hepatitis Hepat Res Treat 2013 2013 472027 24232179
97 Poole BD Zhou J Grote A Schiffenbauer A Naides SJ Apoptosis of liver-derived cells induced by parvovirus B19 nonstructural protein J Virol 2006 80 4114 4121 16571827
98 Poole BD Karetnyi YV Naides SJ Parvovirus B19-induced apoptosis of hepatocytes J Virol 2004 78 7775 7783 15220451
99 Zakrzewska K Arvia R Bua G Margheri F Gallinella G Parvovirus B19: Insights and implication for pathogenesis, prevention and therapy Aspects Mol Med 2023 1 100007
100 Krygier DS Steinbrecher UP Petric M Erb SR Chung SW Scudamore CH Buczkowski AK Yoshida EM Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation World J Gastroenterol 2009 15 4067 4069 19705505
101 Islek A Keskin H Agın M Aksungur N Korkut E Ozturk G Parvovirus B19 Infection as a Rare Cause of Fulminant Liver Failure: A Case Report Transplant Proc 2019 51 1169 1171 31101193
102 Chandramouli S Medina-Selby A Coit D Schaefer M Spencer T Brito LA Zhang P Otten G Mandl CW Mason PW Dormitzer PR Settembre EC Generation of a parvovirus B19 vaccine candidate Vaccine 2013 31 3872 3878 23827313
103 James C Harfouche M Welton NJ Turner KM Abu-Raddad LJ Gottlieb SL Looker KJ Herpes simplex virus: global infection prevalence and incidence estimates, 2016 Bull World Health Organ 2020 98 315 329 32514197
104 Riediger C Sauer P Matevossian E Müller MW Büchler P Friess H Herpes simplex virus sepsis and acute liver failure Clin Transplant 2009 23 Suppl 21 37 41 19930315
105 Hashimoto K Minagawa H Yanagi Y Caspase-dependent apoptosis in fulminant hepatic failure induced by herpes simplex virus in mice J Hepatol 2003 39 773 778 14568260
106 Prétet JL Pelletier L Bernard B Coumes-Marquet S Kantelip B Mougin C Apoptosis participates to liver damage in HSV-induced fulminant hepatitis Apoptosis 2003 8 655 663 14739611
107 Levitsky J Duddempudi AT Lakeman FD Whitley RJ Luby JP Lee WM Fontana RJ Blei AT Ison MG US Acute Liver Failure Study Group Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure Liver Transpl 2008 14 1498 1504 18825709
108 McCormack AL Rabie N Whittemore B Murphy T Sitler C Magann E HSV Hepatitis in Pregnancy: A Review of the Literature Obstet Gynecol Surv 2019 74 93 98 30756123
109 Krishnan R Stuart PM Developments in Vaccination for Herpes Simplex Virus Front Microbiol 2021 12 798927 34950127
110 Gianchecchi E Cianchi V Torelli A Montomoli E Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects Vaccines (Basel) 2022 10
111 da Costa Lopes J Falcão LFM Martins Filho AJ Carvalho MLG Mendes CCH Olímpio FA do Socorro Cabral Miranda V Dos Santos LC Chiang JO Cruz ACR Galúcio VCA do Socorro da Silva Azevedo R Martins LC Duarte MIS de Sousa JR da Costa Vasconcelos PF Quaresma JAS Factors Involved in the Apoptotic Cell Death Mechanism in Yellow Fever Hepatitis Viruses 2022 14
112 Quaresma JA Barros VL Fernandes ER Pagliari C Takakura C da Costa Vasconcelos PF de Andrade HF Jr Duarte MI Reconsideration of histopathology and ultrastructural aspects of the human liver in yellow fever Acta Trop 2005 94 116 127 15829426
113 Waggoner JJ Rojas A Pinsky BA Yellow Fever Virus: Diagnostics for a Persistent Arboviral Threat J Clin Microbiol 2018 56
114 Song ATW Carneiro D'Albuquerque LA Acute Liver Failure Secondary to Yellow Fever: A Challenging Scenario Clin Liver Dis (Hoboken) 2019 13 58 61 31139357
115 de Freitas CS Higa LM Sacramento CQ Ferreira AC Reis PA Delvecchio R Monteiro FL Barbosa-Lima G James Westgarth H Vieira YR Mattos M Rocha N Hoelz LVB Leme RPP Bastos MM Rodrigues GOL Lopes CEM Queiroz-Junior CM Lima CX Costa VV Teixeira MM Bozza FA Bozza PT Boechat N Tanuri A Souza TML Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo PLoS Negl Trop Dis 2019 13 e0007072 30699122
116 Figueiredo-Mello C Casadio LVB Avelino-Silva VI Yeh-Li H Sztajnbok J Joelsons D Antonio MB Pinho JRR Malta FM Gomes-Gouvêa MS Salles APM Corá AP Moreira CHV Ribeiro AF Nastri ACSS Malaque CMS Teixeira RFA Borges LMS Gonzalez MP Junior LCP Souza TNL Song ATW D'Albuquerque LAC Abdala E Andraus W Martino RB Ducatti L Andrade GM Malbouisson LMS Souza IM Carrilho FJ Sabino EC Levin AS Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study) BMJ Open 2019 9 e027207
117 Duarte-Neto AN Cunha MDP Marcilio I Song ATW de Martino RB Ho YL Pour SZ Dolhnikoff M Saldiva PHN Duarte MIS Takakura CF Lima FR Tanigawa RY Iglezias SD Kanamura CT Dos Santos ABG Perondi B Zanotto PMA D'Albuquerque LAC Alves VAF Yellow fever and orthotopic liver transplantation: new insights from the autopsy room for an old but re-emerging disease Histopathology 2019 75 638 648 31087672
118 Freedman DO Leder K Immunizations for travel. [cited 15 March 2024]. Available from: https://www.uptodate.com/contents/immunizations-for-travel
119 Reno E Quan NG Franco-Paredes C Chastain DB Chauhan L Rodriguez-Morales AJ Henao-Martínez AF Prevention of yellow fever in travellers: an update Lancet Infect Dis 2020 20 e129 e137 32386609
120 Who. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013--recommendations Vaccine 2015 33 76 77 24852721
121 Ahmed-Khan MA Matar G Coombes K Moin K Joseph BM Funk CM Remdesivir-Associated Acute Liver Failure in a COVID-19 Patient: A Case Report and Literature Review Cureus 2023 15 e34221 36852363
122 Morgan K Samuel K Vandeputte M Hayes PC Plevris JN SARS-CoV-2 Infection and the Liver Pathogens 2020 9
123 Shih AR Misdraji J COVID-19: gastrointestinal and hepatobiliary manifestations Hum Pathol 2023 132 39 55 35843340
124 Melquist S Estepp K Aleksandrovich Y Lee A Beiseker A Hamedani FS Bassett J COVID-19 presenting as fulminant hepatic failure: A case report Medicine (Baltimore) 2020 99 e22818 33120805
125 Matsuki Y Sugihara T Kihara T Kawakami T Kitaura T Takata T Nagahara T Fujita K Hirai M Kato M Kawaguchi K Isomoto H COVID-19-Triggered Acute Liver Failure and Rhabdomyolysis: A Case Report and Review of the Literature Viruses 2023 15
126 Sambommatsu Y Mouch C Kulkarni AV Bruno DA Eslami M Imai D Lee SD Khan AA Sharma A Saeed M Cotterell AH Levy MF Morales MK Montenovo MI Rao PN Reddy R Menon B Kumaran V Liver transplantation for post-COVID-19 cholangiopathy: A case series Clin Transplant 2023 37 e15141 37755152
127 Lee A Wein AN Doyle MBM Chapman WC Liver transplantation for post-COVID-19 sclerosing cholangitis BMJ Case Rep 2021 14
128 World Health Organization Coronavirus disease (COVID-19): Vaccines and vaccine safety. World Health Organization. [cited 20 March 2024]. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines-safety
129 Chen Z Tang W Feng N Lv M Meng F Wu H Zhao Y Xu H Dai Y Xue J Wang J Xu A Zhang B Chu D Li Y Wu D Dong L Zhang S Xue R Inactivated vaccines reduce the risk of liver function abnormality in NAFLD patients with COVID-19: a multi-center retrospective study EBioMedicine 2024 99 104912 38096688
130 Roy SK Bhattacharjee S Dengue virus: epidemiology, biology, and disease aetiology Can J Microbiol 2021 67 687 702 34171205
131 Guzman MG Gubler DJ Izquierdo A Martinez E Halstead SB Dengue infection Nat Rev Dis Primers 2016 2 16055 27534439
132 Giri S Anirvan P Vaidya A Praharaj DL Dengue-related acute liver failure-A scoping review Indian J Gastroenterol 2024 43 407 424 38687431
133 Chia PY Thein TL Ong SWX Lye DC Leo YS Severe dengue and liver involvement: an overview and review of the literature Expert Rev Anti Infect Ther 2020 18 181 189 31971031
134 Rajakumar A Gupta P Rammohan A Devarajan V Jothimani D Shanmugam N Kaliamoorthy I Rela M Liver Transplantation for Dengue-induced Acute Liver Failure J Clin Exp Hepatol 2024 14 101405 38660561
135 Sridhar S Luedtke A Langevin E Zhu M Bonaparte M Machabert T Savarino S Zambrano B Moureau A Khromava A Moodie Z Westling T Mascareñas C Frago C Cortés M Chansinghakul D Noriega F Bouckenooghe A Chen J Ng SP Gilbert PB Gurunathan S DiazGranados CA Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy N Engl J Med 2018 379 327 340 29897841
136 World Health Organization WHO position paper on dengue vaccines – May 2024 Wkly Epidemiol Rec 2024 99 203 224
137 Rothenberg M Cheung R Ahmed A Adenovirus-induced acute liver failure Dig Dis Sci 2009 54 218 221 19034647
138 Lynch JP 3rd Kajon AE Adenovirus: Epidemiology, Global Spread of Novel Types, and Approach to Treatment Semin Respir Crit Care Med 2021 42 800 821 34918322
139 Grand RJ Pathogenicity and virulence of human adenovirus F41: Possible links to severe hepatitis in children Virulence 2023 14 2242544 37543996
140 Ronan BA Agrwal N Carey EJ De Petris G Kusne S Seville MT Blair JE Vikram HR Fulminant hepatitis due to human adenovirus Infection 2014 42 105 111 23979854
141 Shayakhmetov DM Gaggar A Ni S Li ZY Lieber A Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity J Virol 2005 79 7478 7491 15919903
142 Ajuebor MN Jin Y Gremillion GL Strieter RM Chen Q Adegboyega PA GammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk J Virol 2008 82 9564 9576 18667515
143 Schaberg KB Kambham N Sibley RK Higgins JPT Adenovirus Hepatitis: Clinicopathologic Analysis of 12 Consecutive Cases From a Single Institution Am J Surg Pathol 2017 41 810 819 28296681
144 Kuschner RA Russell KL Abuja M Bauer KM Faix DJ Hait H Henrick J Jacobs M Liss A Lynch JA Liu Q Lyons AG Malik M Moon JE Stubbs J Sun W Tang D Towle AC Walsh DS Wilkerson D Adenovirus Vaccine Efficacy Trial Consortium A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits Vaccine 2013 31 2963 2971 23623865
145 Verma A Vimalesvaran S Lampejo T Deep A Dhawan A Use of cidofovir in recent outbreak of adenovirus-associated acute liver failure in children Lancet Gastroenterol Hepatol 2022 7 700 702
146 Siew JX Seah XFV Chew YR Thoon KC Chong CY Yung CF Maiwald M Len Y Li J Kam KQ Nadua K Tanugroho R Tan NWH Epidemiology of Adenovirus Infections and Outcomes of Cidofovir Treatment in Severely Ill Children Pediatr Infect Dis J 2020 39 907 913 32404785
147 Banc-Husu AM Moulton EA Shiau H Gutierrez Sanchez LH Desai MS Cerminara D Munoz FM Buffaloe LM Valencia-Deray KG Galvan NTN Bhatnagar J Estetter L Rassaei N Reagan-Steiner S Wicker J Dunn JJ Allen CE Patel KR Harpavat S Goss JA Leung DH Acute liver failure and unique challenges of pediatric liver transplantation amidst a worldwide cluster of adenovirus-associated hepatitis Am J Transplant 2023 23 93 100 36695626
